INTRODUCTION
============

Colorectal cancer (CRC) is the third most common cancer worldwide. Most CRC develops through an adenoma-carcinoma progression sequence, which suggests that the normal colorectal epithelium transforms into an adenoma, then progresses to cancer via the accumulation of progressive molecular changes, including both genetic and epigenetic alterations.[@b1-gnl-10-773],[@b2-gnl-10-773] Epigenetic changes, alterations in the regulation of gene expression that do not involve a change in the DNA sequence of the cell, are carried out via DNA methylation, histone modification and polycomb complex formation.[@b3-gnl-10-773] With regard to the epigenetic alterations observed in CRC, aberrant DNA methylation has been extensively studied.[@b4-gnl-10-773]--[@b7-gnl-10-773]

In carcinogenesis, the "field effect" concept developed from the observation that survivors of certain cancers are prone to develop other malignancies of the same tissue type near the primary cancer.[@b8-gnl-10-773] Epigenetic alteration has a specific role in the field effect and several studies have provided evidence that specific aberrant DNA methylation may be a potential marker of the CRC field effect.[@b9-gnl-10-773],[@b10-gnl-10-773] In the present study, we selected four previously demonstrated promoters, secreted frizzled-related protein 2 (*SFRP2*), tissue factor pathway inhibitor 2 (*TFPI2*), N-Myc downstream-regulated gene 4 (*NDRG4*) and bone morphogenic protein 3 (*BMP3*), to demonstrate the field effect in CRC.

MATERIALS AND METHODS
=====================

1. Sample collection and DNA preparation
----------------------------------------

The study was approved by the Institutional Review Board of Kangbuk Samsung Hospital. All patients provided written informed consent as required by the Institutional Review Board. None of the patients had clinically apparent polyposis syndrome or hereditary nonpolyposis colon cancer syndrome. Patients with inflammatory bowel disease, prior colorectal resection, a history of any cancer, or a major psychological illness were excluded from the study.

Tissue samples were obtained from 34 patients who underwent surgery for CRC and 5 normal subjects without CRC or adenoma who underwent colonoscopy at Kangbuk Samsung Hospital in Seoul, Korea from 2012 to 2013. We examined samples taken from the sigmoid colon of endoscopically normal subjects. We collected samples of primary CRC tissue (T), adjacent normal-appearing tissue (AN), and nonadjacent normal-appearing tissue (NN) from each patient with CRC. All samples of adjacent normal-appearing tissues and nonadjacent normal-appearing tissues were derived from tissue located 2 cm and 8 cm, respectively, from the tumor. The status of all tissue specimens was confirmed histologically. Clinical and pathologic data were obtained for all 34 patients with CRC.

2. Isolation of DNA and sodium bisulfite conversion
---------------------------------------------------

Formalin-fixed, paraffin-embedded tissues were mounted on glass slides and stained with hematoxylin and eosin. Microdis-section and DNA extraction were performed as previously described.[@b11-gnl-10-773]

Epithelium and tumor tissue were carefully microdissected using a microtome (RM2255; Leica, Nussloch, Germany). The dissected tissues were placed individually in 1.5-mL microcentrifuge tubes with phosphate-buffered saline and deparaffinized by heating for 5 minutes at 75°C. The mixtures obtained were then centrifuged at 13,000 rpm for 2 minutes, and the supernatants were removed. Pellets were mixed with DNA extraction buffer (Biosewoom, Seoul, Korea) and heated for 5 minutes at 56°C, and an additional 8 minutes at 100°C to destroy the cells and remaining tissues. The mixtures obtained were then centrifuged at 13,000 rpm for 2 minutes, and the supernatants, which contained DNA, were then used for further studies. Genomic DNA was chemically modified by sodium bisulfite to convert all unmethylated cytosines to uracils while leaving the methylcytosines unaltered (EZ DNA Methylation^TM^ kit; Zymo Research, Irvine, CA, USA).

3. Methylation-specific PCR
---------------------------

Methylation of the *SFRP2*, *TFPI2*, *NDRG4* and *BMP3* promoters in the bisulfite-modified DNA was investigated using methylation-specific PCR (MSP) with primer pairs designed to specifically amplify methylated or unmethylated alleles. The nucleotide sequences of the primers previously reported are listed in [Table 1](#t1-gnl-10-773){ref-type="table"}. Commercially available methylated human genomic DNA (CpGenome^TM^ Universal Methylated DNA; Chemicon International, Temecula, CA, USA) was used as a positive control for unmethylated and methylated alleles and reagents without the addition of DNA served as negative controls. The thermocycler conditions were, in general, as follows: 95°C for 15 minutes, 39 cycles of 95°C for 30 seconds, specific annealing temperature for 30 to 60 seconds, 72°C for 30 seconds, followed by a final extension at 72°C for 10 minutes ([Table 1](#t1-gnl-10-773){ref-type="table"}). The MSP products were then subjected to horizontal gel electrophoresis through 1.2% agarose gel, stained with ethidium bromide and visualized with UV transillumination by using the Quality One Image Analyzer system (Bio-Rad, Hercules, CA, USA) ([Fig. 1](#f1-gnl-10-773){ref-type="fig"}). Normalization of methylation level (%) was defined based on the following calculation: (Measured-negative control/positive control-negative control).

4. Statistics
-------------

Presence of methylated promoters was analyzed initially as a categorical variable (negative, methylation level \<20%; positive, methylation level \>20%). The cutoff value was selected because lower marginal values could not be distinguished from background staining of the gels, as described in the previous study.[@b12-gnl-10-773] We analyzed the levels of methylation as a continuous variable. We computed means, standard deviations, medians, and ranges with levels of methylation and analyzed data with one-way analysis of variance followed by Tukey's posttest. The differences in the methylation frequency of each promoter between patients with CRC and normal subjects were analyzed using the Fisher exact test. The association between levels of methylated promoter and clinicopathological variables was analyzed using the Mann-Whitney test or Kruskal-Wallis test. All reported p-values were two-sided, and p-values \<0.05 indicated statistical significance. Statistical analysis was performed using PASW 18.0 version software (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

A total of 39 samples from 34 patients with CRC (mean age, 57.0 years old; range, 36 to 80 years; 22 male and 12 female) and five normal subjects (mean age, 68.2 years old; range, 56 to 86 years; three male and two female) were analyzed. Clinicopathologic features of the patients with CRC are shown in [Table 2](#t2-gnl-10-773){ref-type="table"}. Nodal spread and distant metastasis were detected in 17.6% and 32.4%, respectively.

1. Methylation frequency and levels of methylation of the *SFRP2* promoter
--------------------------------------------------------------------------

When analyzed as a categorical variable, promoter hypermethylation of *SFRP2* in tumor tissues was observed in 27 of the 34 patients with CRC (79.4%). Among these 27 patients with methylation-positive tumor tissue, promoter hypermethylation of *SFRP2* was observed in adjacent normal-appearing tissue in 17 (63.0%) patients and in 19 nonadjacent normal-appearing tissue samples (70.4%). Levels of methylation in tumor tissue, adjacent normal-appearing tissue, and nonadjacent normal-appearing tissue are shown in [Table 3](#t3-gnl-10-773){ref-type="table"} and [Fig. 2](#f2-gnl-10-773){ref-type="fig"}. Levels of methylated *SFRP2* promoter in tumor tissue were significantly higher than in adjacent normal-appearing tissue or nonadjacent normal-appearing tissue (p=0.013).

2. Methylation frequency and levels of methylation of the *TFPI2* promoter
--------------------------------------------------------------------------

Promoter hypermethylation of *TFPI2* in tumor tissue was observed in 28 of the 34 patients with CRC (82.4%). Of these 28 patients, promoter hypermethylation of *TFPI2* was also observed in adjacent normal-appearing tissue in 15 (53.6%) patients and in 17 nonadjacent normal-appearing tissue samples (60.7%). Levels of methylated *TFPI2* promoter in tumor tissue appeared to be significantly higher than in adjacent normal-appearing tissue or nonadjacent normal-appearing tissue (p\<0.001).

3. Methylation frequency and levels of methylation of the *NDRG4* promoter
--------------------------------------------------------------------------

For the *NDRG4* promoter, promoter hypermethylation in tumor tissue was observed in 26 of the 34 patients with CRC (76.5%). Of these 26 patients, promoter hypermethylation of *NDRG4* was observed in adjacent normal-appearing tissue in 16 patients (61.5%) and in 18 nonadjacent normal-appearing tissue samples (69.2%). Levels of methylated *NDRG4* in tumor tissue were significantly higher than in adjacent normal-appearing tissue or nonadjacent normal-appearing tissue (p=0.003).

4. Methylation frequency and levels of methylation of the *BMP3* promoter
-------------------------------------------------------------------------

Promoter hypermethylation of *BMP3* in tumor tissue was observed in 14 out of the 34 patients with CRC (41.2%). Of these 14 patients, methylation frequency of the *BMP3* promoter was observed in five adjacent normal-appearing tissue samples (35.7%) and in seven nonadjacent normal-appearing tissue samples (50.0%). Levels of methylated *BMP3* in tumor tissue were significantly higher than both normal-appearing tissues (p=0.001).

5. Promoter methylation frequency of individual genes in normal subjects and methylation-negative CRC patients
--------------------------------------------------------------------------------------------------------------

Normal subjects did not exhibit methylation of each tested promoter. Mean levels of methylated promoters in normal subjects were observed to be low (*SFRP2*, 1.6%; *TFPI2*, 0.23%; *NDRG4*, 1.72%; *BMP3*, 0.86%). Promoter hypermethylation of *SFRP2*, *TFPI2*, *NDRG4* and *BMP3* in tumor tissues was not observed in seven (20.5%), six (17.6%), eight (23.5%), and 20 (58.8%) patients. Of these patients, the methylation frequency of *SFRP2*, *TFPI2*, *NDRG4* and *BMP3* was 0%/42.8% (3/7), 0%/50% (3/6), 37.5% (3/8) and 0%/10% (2/20) in adjacent/nonadjacent normal-appearing tissues respectively.

6. Levels of methylated promoters in tumor tissue and clinicopathologic features
--------------------------------------------------------------------------------

The association between methylated promoters in tumor tissue and clinicopathologic features is shown in [Table 4](#t4-gnl-10-773){ref-type="table"}. There was no statistically significant association observed between the methylated promoters in tumor tissue and patient age, sex, smoking status, tumor size, nodal status, metastasis or TNM stage. In correlation analysis of methylation level and age, there was a trend toward a higher level of *SFRP2* (58.2 vs 43.9, p=0.08) and *NDRG4* (59.7 vs 37.3, p=0.07) in age ≥60 compared to age \<60 patients. In correlation analysis of methylation frequency and level with tumor location, there was a trend toward a higher frequency and level of *NDRG4* (frequency, 100% vs 71.4%, p=0.29; level, 54.6 vs 43.5, p=0.46) and *BMP3* (frequency, 66.7% vs 35.7%, p=0.20; level, 34.5 vs 30.0, p=0.57) promoters in the right colon than the left colon. There was no difference in methylation frequency or the levels of the four promoters between the colon and rectum (data not shown).

DISCUSSION
==========

In this study, hypermethylation of *SFRP2*, *TFPI2*, *NDRG4*, and *BMP3* was observed in normal-appearing tissue of patients with CRC and demonstrated the field effect in CRC. The methylation frequency in normal-appearing tissue was over 50% for each promoter. In addition, we also showed that the field effect was observed not only in adjacent normal-appearing tissue, but also in nonadjacent normal-appearing tissue.

In colorectal carcinogenesis, the possibility of field cancerization was first proposed due to the increased occurrence of flat dysplasia and CRC in patients with inflammatory bowel disease.[@b13-gnl-10-773] In cases of sporadic CRC, individuals who had a personal history of colon adenoma or adenocarcinoma were at increased risk of developing metachronous adenoma or adenocarcinoma[@b14-gnl-10-773] and these results supported that the field effect may occur in the colon and could consequently increase the risk of CRC. Recent studies showed that there were several changes such as increased occurrence of chromosomal aberrations or aberrant DNA methylation in the normal colon mucosa adjacent to colon cancer.[@b15-gnl-10-773]

Aberrant DNA methylation is a key mechanism of tumor suppressor gene inactivation in certain malignancies including CRC, and many genes that are targets of aberrant methylation have been identified.[@b4-gnl-10-773] However, only a few studies have demonstrated the field effect and assessed the methylation status of specific loci in normal colon mucosa. In previous studies, methylation of five genes (*RUNX3*, *SOCS1*, *NEUROG1*, *CACNA1G*, and *IGF2*) was found to be increased in the morphologically normal colon mucosa of patients with advanced proximal sessile polyps, a precursor lesion to CpG island methylator phenotype (CIMP) cancers.[@b16-gnl-10-773] In addition to *CIMP* genes, methylation of the O[@b6-gnl-10-773]-methylguanine-DNA methyltransferase (*MGMT*) gene promoter was detected in normal-appearing mucosa adjacent to CRC, which was methylated in 46% of colorectal tumors and in 26% of corresponding adjacent normal-appearing mucosa.[@b12-gnl-10-773] Grady *et al*.[@b17-gnl-10-773] suggested another locus, *EVL/miR-342*, to be a marker of field cancerization in the colon, and found methylation in 86% of colorectal adenocarcinomas, 56% of histologically normal colorectal mucosa 10 cm away from CRC, and in 12% of normal colorectal mucosa from individuals without CRC.

We selected four promoters, *SFRP2*,[@b18-gnl-10-773]--[@b20-gnl-10-773] *TFPI2*,[@b21-gnl-10-773] *NDRG4*,[@b22-gnl-10-773] and *BMP3*,[@b23-gnl-10-773] as they previously showed aberrant DNA methylation in CRC tumor tissue with high sensitivity and specificity compared with normal subjects and were included in the recent multitarget stool DNA test.[@b24-gnl-10-773],[@b25-gnl-10-773] Aberrant *Wnt* pathway signaling is observed in approximately 90% of CRC tumors; *SFRP*s possess a domain similar to *Wnt*-receptor frizzled proteins and can inhibit *Wnt* receptor binding to downregulate pathway signaling during development.[@b26-gnl-10-773],[@b27-gnl-10-773] In a previous study, methylation of the *SFRP2* promoter was present in over 60% of advanced CRC cases and in less than 3.1% of normal subjects.[@b19-gnl-10-773] *TFPI2* is a Kunitz-type serine proteinase inhibitor that protects the extracellular matrix of cancer cells from degradation and inhibits in vitro colony formation and proliferation.[@b28-gnl-10-773],[@b29-gnl-10-773] Methylation of *TFPI2* was detected with a high frequency in over 62% of CRC patients, and *TFPI2* was more frequently methylated in well-differentiated colorectal carcinomas and lymph node metastases.[@b21-gnl-10-773] *NDRG4* is a member of the *NDRG* protein family that showed 57% to 65% amino acid sequence homology. *NDRG4* was suggested to be a tumor suppressor gene in CRC whose expression is frequently inactivated by promoter methylation.[@b30-gnl-10-773] In a previous study, methylation of the *NDRG4* gene was detected in over 86% of CRC patients and in less than 4% of normal subjects.[@b22-gnl-10-773] *BMP*s are members of the *TGFβ* growth factor superfamily and disrupted *BMP* signaling in tumor development has recently been studied.[@b23-gnl-10-773],[@b31-gnl-10-773] *BMP3* inactivation was observed in early-onset tumorigenesis of colorectal cancer and approximately 55% of CRC patients showed *BMP3* promoter methylation.[@b23-gnl-10-773] In this study, the methylation frequency of CRC was over 75% for each promoter except *BMP3*, which was in agreement with previous studies.[@b19-gnl-10-773],[@b21-gnl-10-773],[@b22-gnl-10-773] However, even though there was a trend toward a higher level of methylation in older patients, there was no significant association between methylation status and clinicopathologic features.

Our results showed that the methylation frequency of normal-appearing tissue in patients was over 50% for each promoter, thus demonstrating the field effect. To evaluate the extent of the field effect, we obtained normal-appearing mucosal specimens that were located 2 and 8 cm from the CRC, and provided evidence that the field effect was also observed in nonadjacent normal-appearing tissue in patients with CRC. These results are consistent with a previous study in which *MGMT* methylation was detected 10 cm away from tumor tissue in 77% of cases.[@b12-gnl-10-773] In addition, we compared methylation frequencies and levels between adjacent and nonadjacent normal-appearing tissues, but the results were similar. These findings suggest that the field effect occurs in CRC, but the mechanism of tumorigenesis from the cancerized field is not yet clear.

There are several limitations to our study. First, this study examined a limited number of cases. A large study should be performed to examine the field effect in CRC with the genes investigated in this study. Second, the distance between adjacent and nonadjacent normal appearing tissue might have been insufficient. In our study, 8 cm from CRC tissues was the maximum distance used due to the limitations associated with resected specimens. Although there is no standard distance between adjacent and nonadjacent tissues, samples further from CRC tissues should be examined to investigate the extent of the field effect. Third, real-time quantitative MSP was not available in our study. Further studies with more sensitive MSP assays are needed.

In conclusion, this study provides evidence that the field effect is present in CRC, and that it affects both adjacent and non-adjacent normal-appearing mucosa. The levels of methylated promoters and methylation frequency in CRC tumor tissues are higher than in adjacent and nonadjacent normal-appearing mucosa. Further research is needed to validate methylated promoters as a biomarker for CRC, to clarify the biological mechanisms of the field effect in CRC and to evaluate the usefulness of DNA methylation levels as a risk marker of CRC.
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![Representative methylation-specific polymerase chain reaction of promoters in tissues. (a) *SFRP2*; (b) *TFPI2*; (c) *NDRG4*; and (d) *BMP3*.\
NC, negative control; PC, positive control; NN, nonadjacent normal-appearing tissue; AN, adjacent normal-appearing tissue; T, primary colorectal tumor tissue; *SFRP2*, secreted frizzled-related protein 2; *TFPI2*, tissue factor pathway inhibitor 2; *NDRG4*, N-Myc downstream-regulated gene 4; *BMP3*, bone morphogenic protein 3.](gnl-10-773f1){#f1-gnl-10-773}

![Distribution of methylation level (%) for nonadjacent normal-appearing tissue (NN), adjacent normal-appearing tissue (AN), and primary colorectal tumor tissue (T) in (A) *SFRP2*, (B) *TFPI2*, (C) *NDRG4*, and (D) *BMP3*, respectively.\
*SFRP2*, secreted frizzled-related protein 2; *TFPI2*, tissue factor pathway inhibitor 2; *NDRG4*, N-Myc downstream-regulated gene 4; *BMP3*, bone morphogenic protein 3. \*p\<0.05.](gnl-10-773f2){#f2-gnl-10-773}

###### 

Summary of the Primer Sequences, Polymerase Chain Reaction (PCR) Product Sizes and Annealing Temperatures Used for Methylation-Specific PCR Assays

  Gene          Primer sequence (5′→3′)            PCR product size, bp   Annealing temperature, °C
  --------- --- ---------------------------------- ---------------------- ---------------------------
  *SFRP2*   M   S: GGGTCGGAGTTTTTCGGAGTTGCGC       138                    62
                A: CCGCTCTCTTCGCTAAATACGACTCG                             
            U   S: TTTTGGGTTGGAGTTTTTTGGAGTTGTGT   145                    50
                A: ACCCACTCTCTTCACTAAATACAACTCA                           
  *BMP3*    M   S: GTTTGGAGTTTAATTTTCGGTTTC        179                    54
                A: ATAACTTCGATCTCTCTCCCTACG                               
            U   S: GGTTTGGAGTTTAATTTTTGGTTTT       178                    54
                A: AACTTCAATCTCTCTCCCTACACC                               
  *NDRG4*   M   S: TTTAGGTTCGGTATCGTTTCGC          110                    61
                A: CGAACTAAAAACGATACGCCG                                  
            U   S: GATTAGTTTTAGGTTTGGTATTGTTTTGT   105                    61
                A: AAAACCAAACTAAAAACAATACACCA                             
  *TFPI2*   M   S: ATTTTTTAGGTTTCGTTTCGGC          118                    57
                A: GCCTAACGAAAAAAAATACGCG                                 
            U   S: TTAGTTATTTTTTAGGTTTTGTTTTGGT    105                    57
                A: AAAACACCTAACAAAAAAAAATACACA                            

bp, base pair; *SFRP2*, secreted frizzled-related protein 2; M, methylated; S, sense; A, antisense; U, unmethylated; *BMP3*, bone morphogenic protein 3; *NDRG4*, N-Myc downstream-regulated gene 4; *TFPI2*, tissue factor pathway inhibitor 2.

###### 

Clinicopathological Features of the Patients

  Clinicopathologic feature                              No. of patients (%)
  ------------------------------------------------------ ---------------------------------------
  Total no.                                              34
  Age, yr                                                
   ≤60                                                   22 (64.7)
   \>60                                                  12 (35.3)
  Sex                                                    
   Male                                                  22 (64.7)
   Female                                                12 (35.3)
  Smoking                                                
   Nonsmoker                                             26 (76.5)
   Ex-smoker                                             5 (14.7)
   Current smoker                                        3 (3.0)
  TNM stage[\*](#tfn3-gnl-10-773){ref-type="table-fn"}   
   T1/T2/T3/T4                                           2 (5.9)/4 (11.8)/24 (70.6)/4 (11.8)
   N0/N1/N2                                              16 (47.1)/12 (35.3)/6 (17.6)
   M0/M1                                                 23 (37.6)/11 (32.4)
   Stage I/II/III/IV                                     5 (14.7)/8 (23.5)/11 (32.4)/10 (29.4)

T, tumor; N, node; M, metastasis.

Tumor stage was determined with the use of the American Joint Committee on Cancer (AJCC) staging system (2009).

###### 

Methylation Levels of *SFRP2*, *TFPI2*, *NDRG4*, and *BMP3*

               Mean±SD     p-value   
  ------------ ----------- --------- -------
  *SFRP2*, %                         
   NN          29.9±16.5   0.039     0.013
   AN          29.4±21.3   0.021     
   T           49.8±26.1             
  *TFPI2*, %                         
   NN          24.1±14.6   0.000     0.000
   AN          23.6±18.4   0.000     
   T           59.5±21.4             
  *NDRG4*, %                         
   NN          33.8±21.8   0.024     0.003
   AN          30.0±21.9   0.004     
   T           51.8±27.5             
  *BMP3*, %                          
   NN          16.9±13.6   0.003     0.001
   AN          17.9±16.3   0.004     
   T           35.7±10.8             

*SFRP2*, secreted frizzled-related protein 2; *TFPI2*, tissue factor pathway inhibitor 2; *NDRG4*, N-Myc downstream-regulated gene 4; *BMP3*, bone morphogenic protein 3; ANOVA, analysis of variance; NN, non-adjacent normal appearing tissue; AN, adjacent normal appearing tissue; T, primary tumor tissue.

###### 

Clinicopathological Features and Methylation of *SFRP2*, *TFPI2*, *NDRG4* and *BMP*

  Clinicopathological feature                            *SFRP2*     *TFPI2*   *NDRG4*     *BMP3*                                   
  ------------------------------------------------------ ----------- --------- ----------- -------- ----------- ------- ----------- -------
  Total positive                                         27          28        26          14                                       
  Age, yr                                                            0.681                 0.578                0.077               0.225
   ≤60                                                   17 (63.0)             17 (60.7)            16 (61.5)           11 (78.6)   
   \>60                                                  10 (37.0)             11 (39.3)            10 (38.5)           3 (21.4)    
  Sex                                                                0.624                 0.498                0.070               0.662
   Male                                                  19 (70.4)             19 (67.9)            18 (69.2)           8 (57.1)    
   Female                                                8 (29.6)              9 (32.1)             8 (30.8)            6 (32.9)    
  Smoking                                                            0.490                 0.902                0.811               0.468
   Nonsmoker                                             19 (70.4)             22 (78.6)            19 (73.1)           11 (78.6)   
   Ex-smoker                                             5 (18.5)              4 (14.3)             4 (15.4)            2 (14.3)    
   Current smoker                                        3 (11.1)              2 (7.1)              3 (11.5)            1 (7.1)     
  Tumor depth                                                        0.344                 0.416                0.364               0.498
   T1                                                    2 (7.4)               2 (7.1)              1 (3.8)             0           
   T2                                                    4 (14.8)              3 (10.7)             4 (15.4)            3 (21.4)    
   T3                                                    17 (63.0)             19 (67.9)            17 (65.4)           10 (71.5)   
   T4                                                    4 (14.8)              4 (14.3)             4 (15.4)            1 (7.1)     
  Nodal status                                                       0.180                 0.853                0.150               0.205
   N0                                                    14 (51.9)             13 (46.4)            11 (42.3)           9 (64.3)    
   N1                                                    8 (29.6)              11 (39.3)            9 (34.6)            5 (35.7)    
   N2                                                    5 (18.5)              4 (14.3)             6 (23.1)            0           
  Metastasis                                                         0.109                 0.382                0.979               0.839
   M0                                                    19 (70.4)             18 (64.3)            15 (57.7)           10 (71.4)   
   M1                                                    8 (29.6)              10 (35.7)            11 (42.3)           4 (28.6)    
  TNM stage[\*](#tfn6-gnl-10-773){ref-type="table-fn"}               0.120                 0.399                0.092               0.798
   I                                                     5 (18.5)              4 (14.3)             4 (15.4)            2 (14.2)    
   II                                                    6 (22.3)              6 (21.4)             4 (15.4)            4 (28.6)    
   III                                                   8 (29.6)              8 (28.6)             8 (30.8)            4 (28.6)    
   IV                                                    8 (29.6)              10 (35.7)            10 (38.4)           4 (28.6)    

*SFRP2*, secreted frizzled-related protein 2; *TFPI2*, tissue factor pathway inhibitor 2; *NDRG4*, N-Myc downstream-regulated gene 4; *BMP3*, bone morphogenic protein 3; T, tumor; N, node; M, metastasis.

Tumor stage was determined with the use of the American Joint Committee on Cancer (AJCC) staging system (2009).
